Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity.
OBJECTIVE
To evaluate the long term efficacy and safety of the use of propiverine and terazosine combination in patients with LUTS and DO by a placebo controlled study.


METHODS
One hundred patients were enrolled in the study. They were randomized into two groups (each group consisted of 50 patients). Terazosine and placebo were administered to the patients in Group 1 and terazosine plus propiverine HCL was administered to Group 2. The patients were evaluated by international prostate symptom score (IPSS), the first four questions of IPSS (IPSS4), the 8th question of IPSS (quality of life-QoL), overactive bladder symptom score questionnaire (OAB-q V8), PSA test, urodynamic studies, post voiding residue (PVR). All patients were followed for one year and were reassessed for comparison.


RESULTS
IPSS, IPSS4, OAB symptoms, QoL score, PVR, and Qmax scores of the groups did not differ. After one year treatment, there was significant improvement in IPSS, IPSS4, OAB symptoms, QoL and Qmax values in Group 2. No significant improvement was noted for the same parameters in Group 1.


CONCLUSIONS
This is the first study to show long term safety and efficacy of anticholinergic therapy for patients with LUTS. In patients with OAB or DO, long term anticholinergic treatment may be regarded as a treatment option.
Department of Urology, Adana Numune Education and Research Hospital, Turkey.
Nevzat Can
NC
Sener
Ufuk
U
Ozturk
H N Goksel
HN
Goktug
Adnan
A
Gucuk
Ismail
I
Nalbant
Suleyman
S
Yesil
M Imamoglu
MI
Abdurrahim
D000328:Adult; D001561:Benzilates / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001561:Benzilates; D018727:Muscarinic Antagonists; C015586:propiverine; C041226:Terazosin; D011224:Prazosin